This work was conducted in entirety at the Cummings School of Veterinary Medicine at Tufts University.
Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs
Article first published online: 28 JUL 2009
© Veterinary Emergency and Critical Care Society 2009
Journal of Veterinary Emergency and Critical Care
Volume 19, Issue 4, pages 369–374, August 2009
How to Cite
Abelson, A. L., Shelton, G. D., Whelan, M. F., Cornejo, L., Shaw, S. and O'Toole, T. E. (2009), Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs. Journal of Veterinary Emergency and Critical Care, 19: 369–374. doi: 10.1111/j.1476-4431.2009.00433.x
This study was not supported by any funding agency.
- Issue published online: 12 AUG 2009
- Article first published online: 28 JUL 2009
- acetylcholine receptor antibody;
- immunosuppressive agents;
- neuromuscular disease;
- purine analog
Objective – To describe the use of IV and oral mycophenolate mofetil (MMF) as adjunctive therapy in 3 dogs with severe generalized myasthenia gravis.
Case Series Summary – Three dogs suffering from severe generalized myasthenia gravis as confirmed by acetylcholine antibody titers were treated with MMF as part of their treatment regimens. All 3 dogs had radiographic evidence of megaesophagus and suffered from severe regurgitation. Each dog was initially treated with pyridostigmine and supportive agents. When clinical remission was not achieved, IV MMF was administered to all dogs. Signs of clinical remission were apparent within 48 hours and all dogs were later maintained on oral MMF following resolution of regurgitation.
New or Unique Information Provided – This is the first report of the use of IV MMF as adjunctive treatment in dogs with severe generalized myasthenia gravis. Outcome was favorable in all 3 dogs and no adverse effects were noted from the MMF.